Envisagenics

Envisagenics is pleased to welcome Kalpana Merchant, Ph.D., to our Board of Directors! Dr. Merchant brings more than 30 years of expertise in drug discovery and development, with a specialized focus on translational approaches for neurodegenerative disorders, including Alzheimer’s and Parkinson’s disease. Dr. Merchant's extensive experience and strong leadership will be invaluable as we continue to advance our mission. Read the full press release here: https://lnkd.in/eEHqRrvH #Envisagenics #Neuro #Biopharma #DrugDevelopment

Intern Spotlight: Meet Saumil Chukka! Join us this summer as we learn more about the dedicated interns working at Envisagenics. Up first is Data Science Intern Saumil Chukka!  Hometown: Virginia School: The University of Virginia Degree: Computer Science and Neuroscience Class: 2026 Why intern at Envisagenics: "I'm interested in the intersection of Computer Science and Biology, particularly how Machine Learning can be used to predict and determine biological patterns. I was intrigued by Envisagenics' goal to use Machine Learning to identify novel therapeutics for future drug development." What are some of your interests outside of work: "In my free time, I play and watch a lot of soccer, try different types of food, and travel." What are your plans after completing this internship: "After this internship, I will go into my 3rd Year at the University of Virginia. After I graduate, I hope to work toward a Master's Degree in Data Science or Bioinformatics."

Martin Akerman, Co-Founder and CTO of Envisagenics, will be speaking at the upcoming RNA Therapeutics USA 2024 Conference. Martin will present SpliceCore, Envisagenics' AI-driven platform designed to uncover novel therapeutic targets for neurodegenerative diseases like ALS. This platform leverages the intricate process of alternative splicing, which is crucial in neuronal function and disease. We hope you can join us at RNA Therapeutics USA in October: https://bit.ly/3XWNmXd #SAERNA #DrugDiscovery #RNA #AI

Envisagenics had an amazing company outing at Cold Spring Harbor Laboratory on Long Island in late June! As a spin-out of Cold Spring Harbor Laboratory, it was great to bring the majority of the Envisagenics team back to where it all started for professional headshots, a tour of the laboratory, talks by distinguished CSHL speakers, a happy hour, and barbecue. This gathering provided a fantastic opportunity for the primarily remote Envisagenics team to connect and engage in person!

Happy 4th of July! Envisagenics is wishing everyone a safe and joyous Independence Day filled with celebration and pride. During this holiday time, we wish our hardworking team rest and relaxation that is so well deserved. #IndependenceDay #FourthOfJuly #CelebrateFreedom

Thank you to PwC and Life Science Cares New York for hosting a great networking event on Tuesday. Jonathan Abebe, Ph.D., Bioinformatics Scientist at Envisagenics, joined an experienced panel with Geoff Brzuchalski, Jennifer Hawks Bland, Nolan Townsend and Kyle Carver to discuss career paths with the Project Onramp summer internship cohort.  About the experience, Jonathan said, "The highlight of the night was having the opportunity to discuss students' passions and share insights from my own experiences. I look forward to similar events in the future that will allow me to mentor students, an experience that has been invaluable for my own career progression." #innovation #careerdevelopment #envisagenics #drugdiscovery

Thank you to Cure. and The New York Academy of Sciences for including Maria Luisa Pineda, PhD., Envisagenics co-founder and CEO, on a panel exploring the science and business of AI for drug discovery and diagnostics. She was joined by George Church (Harvard University / Massachusetts Institute of Technology), Thomas Fuchs (Icahn School of Medicine at Mount Sinai / Hasso Plattner Institute) and Grant W Mitchell, MD, MBA (Every Cure). Together, they explored challenges with AI such as data quality and integration, regulatory hurdles, scalability and funding. Despite these challenges, the panelists expressed that AI is driving significant breakthroughs, reducing development costs, and enhancing the precision of diagnostics, ultimately revolutionizing the healthcare landscape. #innovation #biotech #drugdiscovery #AI

The science and business of AI for drug discovery and diagnostics are advancing rapidly, utilizing cutting-edge machine learning algorithms and vast datasets to expedite the identification of new drug candidates and streamline diagnostic processes. Last night, Cure. and The New York Academy of Sciences hosted an exceptional panel discussion on this topic. Prof. Nicholas Dirks from The New York Academy of Sciences set the stage for an in-depth dialogue featuring George Church (Harvard University / Massachusetts Institute of Technology), Thomas Fuchs (Icahn School of Medicine at Mount Sinai / Hasso Plattner Institute), Grant W Mitchell, MD, MBA (Every Cure), and Maria Luisa Pineda, PhD. (Envisagenics), with Seema Kumar, CEO of Cure. moderating the discussion. While challenges were identified —such as data quality/integration, regulatory hurdles, scalability, and funding— it was also expressed that AI is driving significant breakthroughs, reducing development costs, and enhancing the precision of diagnostics, ultimately revolutionizing the healthcare landscape. Thanks to all who helped make this special event happen including Seema Kumar, Caroline D., Susanna Ling, Lauren Ruotolo, Jamila Watkins, and Robin Beth Stephenson. #AI #ArtificialIntelligence #AIDrivenDrugDiscovery

Next month, July 24-28, Envisagenics Co-founder and CTO, Martin Akerman, will be presenting our AI-based advancements in drug discovery at Bio Asia in Taipei, Taiwan. Don’t miss this opportunity to connect with Martin Akerman and other leading experts in the biotech industry. BIO One-on-One Partnering is now open! https://bit.ly/3VYLgoi

We’re very pleased to see our co-founder and CTO Martin Akerman featured in Biotechnology Innovation Organization's "5 Takeaways About the Biotech Ecosystem" following his participation in the June 4th panel "AI's Trial by Fire: Experimental Validation in Drug Discovery." Thank you to Biotechnology Innovation Organization for the opportunity. https://lnkd.in/dqwYWeH3 #BIO2024 #Biotech #Innovation #Envisagenics